🔎 Trials Near Me

Beranda › Degenerasi Makula › Illinois

Uji klinis Degenerasi Makula di Illinois

13 studi untuk Degenerasi Makula mencari peserta di lokasi di Illinois.

Kota di Illinois

Teks studi resmi (Bahasa Inggris)

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)

  • Illinois Retina Associates, Oak Park
  • Springfield Clinic, Springfield
Menerima pesertaFase 2/3
Usia 50 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07440225

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

  • University Retina, Lemont
Menerima pesertaFase 2/3
Usia 60 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT06635148

A Study in Adults With Geographic Atrophy

  • University Retina and Macula Associates, P.C., Lemont
Menerima pesertaFase 2
Usia 60 ke atas · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT07606365

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

  • University of Illinois at Chicago, Chicago
  • Retinal Vitreal Consultants, Chicago
  • The University of Chicago, Chicago
  • dan 3 lainnya
Menerima pesertaFase 3
Usia 50 hingga 85 · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT06541704

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

  • Northwestern Medical Group, Chicago
  • The University of Chicago Medicine Duchossois Center for Advanced Medicine, Chicago
  • Retina Associates, Ltd., Elmhurst
  • dan 1 lainnya
Menerima pesertaFase 2
Usia 55 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT06659445

A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

  • University Retina and Macula Associates, Oak Forest
Menerima pesertaFase 1
Usia 50 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT03178149

A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)

  • University Retina and Macula Associates, Oak Forest
Menerima pesertaStudi observasional
Usia 55 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT07144137

Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration

  • University Retina & Macula Associates, Lemont
Menerima peserta
Usia 60 ke atas · Semua jenis kelamin · Diperbarui 26 Agu 2026 · NCT06662162

A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults

  • University of Illinois Chicago - UI Health, Chicago
Menerima pesertaStudi observasional
Usia 6 ke atas · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT07425574

4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

  • University Retina and Macula Associates, Oak Forest
Menerima pesertaFase 1/2
Usia 50 ke atas · Semua jenis kelamin · Diperbarui 21 Agu 2026 · NCT05197270

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)

  • Illinois Retina Associates, Joliet
  • University Retina & Macula Associates, P.C., Lemont
Menerima pesertaFase 2/3
Usia 50 ke atas · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT07496567

Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration

  • Adverum site 179, Lemont
Menerima pesertaFase 2
Usia 50 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT07630649

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

  • Retina Associates, Ltd., Elmhurst
  • University Retina and Macula Associates, PC, Oak Forest
  • Illinois Retina Associates, Oak Park
  • dan 1 lainnya
Menerima pesertaFase 3
Usia 50 ke atas · Semua jenis kelamin · Diperbarui 16 Apr 2026 · NCT07064759

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.